컨텐츠 내용을 수정할 수 있습니다
Diuretics increase urine output by blocking sodium (and chloride) reabsorption at different parts of the nephron — water follows sodium. The site of action predicts both the strength and the electrolyte effect.
| Nephron site | Class | Transporter blocked | Strength | Potassium effect |
|---|---|---|---|---|
| Proximal tubule | Carbonic anhydrase inhibitor (acetazolamide) | Bicarbonate reabsorption | Weak | ↓K⁺, metabolic acidosis |
| Proximal tubule and loop (osmotic) | Mannitol | Draws water into the tubule | Strong water loss | Variable |
| Thick ascending loop of Henle | Loop diuretics | Na⁺–K⁺–2Cl⁻ cotransporter | Most potent (up to about 20–25% of filtered sodium) | ↓K⁺ |
| Distal convoluted tubule | Thiazide and thiazide-like | Na⁺–Cl⁻ cotransporter | Moderate | ↓K⁺ |
| Collecting duct | Potassium-sparing: aldosterone (mineralocorticoid receptor) antagonists; ENaC blockers | Aldosterone effect or sodium channel | Weak | ↑K⁺ |
Why loop and thiazide diuretics lower potassium: more sodium reaches the collecting duct, where it is exchanged for potassium (and hydrogen ions) — so K⁺ is lost and a metabolic alkalosis can develop.
Calcium: loop diuretics increase calcium excretion (used in hypercalcemia); thiazides decrease it (can raise serum calcium; help prevent calcium kidney stones).
| Drug (generic) | Key use | Key point |
|---|---|---|
| Furosemide (prototype loop) | Edema from HF, cirrhosis, kidney disease; acute pulmonary edema; hypercalcemia; hyperkalemia (adjunct) | IV onset about 5 minutes, oral about 30–60 minutes; oral dose ≈ 2 × IV dose. Give high IV doses slowly — not faster than about 4 mg/min (ototoxicity) |
| Bumetanide, torsemide | Same | About 40 mg oral furosemide ≈ 1 mg bumetanide ≈ 10–20 mg torsemide |
| Ethacrynic acid | Loop diuretic for true sulfonamide allergy | Most ototoxic |
| Hydrochlorothiazide (prototype thiazide) | Hypertension (first-line), mild edema, calcium stone prevention | Less effective at low eGFR |
| Chlorthalidone, indapamide (thiazide-like) | Hypertension | Longer acting; chlorthalidone has shown BP lowering in advanced CKD |
| Metolazone | Added to a loop diuretic for diuretic resistance | Profound diuresis and electrolyte loss — monitor closely |
| Spironolactone (prototype potassium-sparing) | HFrEF, cirrhotic ascites (with furosemide, ratio about 100 mg : 40 mg), resistant hypertension, primary aldosteronism, acne and hirsutism | Hyperkalemia; gynecomastia, menstrual changes |
| Eplerenone | HFrEF, post-MI HF, hypertension | Hyperkalemia; no gynecomastia; contraindicated with strong CYP3A4 inhibitors. For hypertension, also contraindicated with potassium supplements or potassium-sparing diuretics, CrCl < 50 mL/min, or type 2 diabetes with microalbuminuria |
| Finerenone (nonsteroidal MRA) | CKD with type 2 diabetes; HF with LVEF ≥ 40% (FDA 2025) | Hyperkalemia; contraindicated with strong CYP3A4 inhibitors |
| Amiloride, triamterene | With a thiazide to offset potassium loss | Hyperkalemia |
| Mannitol (osmotic) | Raised intracranial pressure; acute glaucoma | 0.25–1 g/kg IV; use an in-line filter (crystals) |
| Acetazolamide (carbonic anhydrase inhibitor) | Glaucoma, prevention of acute mountain sickness, metabolic alkalosis | Paresthesia, hypokalemia, metabolic acidosis, kidney stones |
| Tolvaptan (vasopressin antagonist, "aquaretic") | Euvolemic or hypervolemic hyponatremia | Boxed warning: start (and restart) only in hospital with close sodium monitoring — too-rapid correction can cause osmotic demyelination; not for ADPKD outside its restricted (REMS) program. Also liver injury (limit duration) |
| Class | Key adverse effects |
|---|---|
| Loop | Hypokalemia, hypomagnesemia, hyponatremia, hypocalcemia, hypochloremic metabolic alkalosis, dehydration and hypotension (orthostatic), prerenal AKI, ototoxicity (tinnitus, hearing loss — rapid IV, high doses, kidney failure, aminoglycosides), hyperuricemia and gout, hyperglycemia |
| Thiazide | Hypokalemia, hyponatremia (older women especially), hypomagnesemia, hypercalcemia, hyperuricemia and gout, hyperglycemia, raised lipids, photosensitivity, erectile dysfunction. Hydrochlorothiazide: small increased risk of nonmelanoma skin cancer (FDA label 2020) and rare acute angle-closure glaucoma (eye pain, sudden vision loss) |
| Potassium-sparing | Hyperkalemia (especially with CKD, diabetes, ACE inhibitors, ARBs, potassium supplements); spironolactone — gynecomastia, breast tenderness, menstrual irregularity, decreased libido; triamterene — kidney stones |
| Mannitol | Fluid overload and pulmonary edema (initial volume expansion), electrolyte shifts, AKI at high osmolality, rebound intracranial pressure |
| Acetazolamide | Paresthesia, fatigue, metabolic acidosis, hypokalemia, kidney stones, altered taste of carbonated drinks |
Boxed warning (furosemide, bumetanide): these potent diuretics can cause profound water and electrolyte depletion — dose and monitoring must be individualized.
Pregnancy and lactation: diuretics are not used to treat edema of pregnancy or preeclampsia (they reduce plasma volume). Thiazides may be continued for chronic hypertension under specialist care. Spironolactone and other MRAs are avoided (antiandrogen effects on a male fetus; the 2025 hypertension guideline lists MRAs among drugs to avoid). High-dose diuretics can suppress lactation.
Listed in priority order.
| Test | Normal range | Watch for |
|---|---|---|
| Potassium | 3.5–5.0 mEq/L (mmol/L) | Loop/thiazide: < 3.5 → notify before giving (per protocol). Potassium-sparing: > 5.0 → notify |
| Sodium | 135–145 mEq/L (mmol/L) | Thiazides: hyponatremia (confusion, falls) |
| Magnesium | 1.7–2.2 mg/dL (0.70–0.91 mmol/L) | Low Mg makes hypokalemia hard to correct and raises dysrhythmia risk |
| Creatinine | About 0.6–1.2 mg/dL (53–106 µmol/L) | Rising = volume depletion or kidney injury |
| Glucose, uric acid, calcium | Laboratory reference | Hyperglycemia, gout, hypercalcemia (thiazide) |
| Serum osmolality (mannitol) | 275–295 mOsm/kg | Commonly hold if above about 320 mOsm/kg or per protocol |
There is no specific antidote for diuretics. Overdose or overuse causes:
| Problem | Findings | Action |
|---|---|---|
| Volume depletion | Hypotension, tachycardia, dizziness, syncope, rising BUN and creatinine, low urine output | Hold diuretic, notify, IV isotonic fluids as ordered |
| Severe hypokalemia | Weakness, ileus, U waves, ventricular dysrhythmias, digoxin toxicity | Cardiac monitoring; potassium (and magnesium) replacement per protocol |
| Severe hyponatremia | Confusion, seizures | Emergency care; correct slowly to avoid osmotic demyelination |
| Hyperkalemia (potassium-sparing) | Peaked T waves, wide QRS, bradycardia, arrest (emergency at K⁺ ≥ 6.5 mEq/L or any level with ECG changes) | Stop the drug; IV calcium (stabilizes the heart), insulin with dextrose and inhaled albuterol (shift K⁺ into cells), potassium binders, loop diuretic if kidneys work, dialysis |
| Ototoxicity | Tinnitus, hearing loss, vertigo | Stop or slow infusion, notify; may be permanent |
| Mannitol overload | Pulmonary edema, rising osmolality | Stop, notify; loop diuretic or dialysis per order |
다음 이론을 계속 학습하려면 로그인하세요.
로그인하고 계속 학습필기노트, 하이라이터, 메모는 잘 쓰고 있어?
내보내줘운영진이 검토할게요!
마이페이지에서 차단한 회원을 관리할 수 있어요.